“We are very excited by the growth that we are achieving across the world and are very much looking forward to Arab Health.”
Melbourne, Fla., January 10, 2019 — Erchonia Corporation, the global leader in low level laser therapy technology (“3LT”), today announces the company will be exhibiting at the upcoming 2019 Arab Health Conference at the Dubai World Trade Centre from January 28 to January 31.
Erchonia will share the latest from its non-invasive laser line including the FX 635, FDA market-cleared for chronic lower back pain and chronic heel pain from plantar fasciitis; the Verjú laser, FDA market-cleared for the circumferential reduction of the waist, hips and thighs, and the appearance of cellulite; and the LunulaLaser, FDA market-cleared for clear nail growth in patients with onychomycosis.
“We are very excited by the growth that we are achieving across the world and are very much looking forward to Arab Health,” says Charlie Shanks, VP of Erchonia Corporation.
“After a very successful 2018, we are delighted to continue our expansion,” adds Simon Ramshaw, managing director of UK-based Erchonia Lasers Ltd. “We now have representation in many new European markets and are looking to continue our rapid growth in 2019 and beyond.”
The low level laser technology Erchonia will be exhibiting at Arab Health is backed by extensive clinical data. In the placebo-controlled, randomized, double-blind clinical trial that led to the FX 635’s FDA market clearance, 72.4 percent reported at least a 30 percent decrease in their lower back pain with the laser treatment. Clinical trial data proved average pain reduction in patients of 58 percent. And Erchonia’s Verjú low level laser is the only device proven effective in a double-blind, multi-site, placebo-controlled study that delivered an average four-inch loss after two weeks of treatment. The FDA also cleared LunulaLaser when 89 percent of patients responded to treatment in a clinical trial, seeing clear, healthy nail growth in as little as four, 12-minute treatments per foot.
For more information on Erchonia, please visit www.erchonia.com.
About Erchonia Corporation
Based in Melbourne, Florida, family-owned Erchonia is the global leader in the manufacturing and development of low level laser therapy technology (“3LT”). From humble beginnings in a garage in 1996, Erchonia today develops and sells the most advanced, non-invasive 3LT medical equipment on the market in over 50 countries. With more than 15 clearances from the FDA, Erchonia remains passionately committed to effective, research-based 3LT solutions for a wide variety of conditions — from managing chronic pain to promoting fat loss. For more information, please visit www.erchonia.com.